Search

Your search keyword '"Fraison, Jean-Baptiste"' showing total 22 results
Start Over Author "Fraison, Jean-Baptiste"
22 results on '"Fraison, Jean-Baptiste"'

1. Prevalence of anti-neutrophil cytoplasmic antibody-associated vasculitis in the south of France, using the capture-recapture method.

Author

Rubenstein, Emma, Henneton, Pierrick, Rivière, Sophie, Casanova, Marie-Laure, Broner, Jonathan, Arnaud, Erik, Oziol, Eric, Quintrec, Moglie Le, Moranne, Olivier, Jorgensen, Christian, Combe, Bernard, Bourdin, Arnaud, Fontaine, Christophe, Schiffmann, Aurélie, Fraison, Jean-Baptiste, Hallé, Olivier, Fraisse, Thibaut, Veysseyre, Frederic, Taieb, Guillaume, and Aerts, Cécile

Subjects
VASCULITIS, CROSS-sectional method, RESEARCH funding, ANTINEUTROPHIL cytoplasmic antibodies, CONFIDENCE intervals
Abstract

Objectives This study aimed to estimate the prevalence of ANCA-associated vasculitis (AAV). That is, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), in Southern France in 2018, and evaluate differences among Europeans and non-Europeans. Methods This population-based, cross-sectional study used four sources (hospitals, community-based physicians, laboratories, National Health Insurance) to identify adults ≥15 years diagnosed with GPA, MPA or EGPA, living in Hérault and Gard in 2018. Cases were defined using the ACR/EULAR classification criteria, and if necessary, the European Medicines Agency algorithm. Prevalence estimates were standardised to the world population and capture-recapture analysis was used to assess the comprehensiveness of the estimation. The influence of geographical origin was evaluated. Results A total of 202 patients were selected, with 86 cases of GPA (42.6%), 85 cases of MPA (42.1%) and 31 cases of EGPA (15.3%). The standardised prevalence estimates per million inhabitants for 2018 were: 103 (95%CI 84–125) for AAV, 48 (95%CI 35–64) for GPA, 39 (95%CI 28–53) for MPA and 16 (95%CI 9–26) for EGPA, 36 (95%CI 25–50) for anti-PR3 positive AAV, 46 (95%CI 34–61) for anti-MPO positive AAV, and 16 (95%CI 9–26) for ANCA-negative AAV. The global estimation of comprehensiveness by capture-recapture analysis was 80.5%. The number of AAV cases was higher for non-European residents (P  = 0.001), particularly for MPA (P   <  0.0001). Conclusion We provide a new estimate of AAV prevalence in France and show a higher prevalence of MPA in non-European patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients

Author

Mekinian, Arsene, Dervin, Guillaume, Lapidus, Nathanael, Kahn, Jean-Emmanuel, Terriou, Louis, Liozon, Eric, Grignano, Eric, Piette, Jean-Charles, Rauzy, Odile Beyne, Grobost, Vincent, Godmer, Pascal, Gillard, Jerome, Rossignol, Julien, Launay, David, Aouba, Achille, Cardon, Thierry, Bouillet, Laurence, Broner, Jonathan, Vinit, Julien, Ades, Lionel, Carrat, Fabrice, Salvado, Clementine, Toussirot, Eric, Versini, Mathilde, Costedoat-Chalumeau, Nathalie, Fraison, Jean Baptiste, Guilpain, Philippe, Fenaux, Pierre, and Fain, Olivier

Published
2017
Full Text
View/download PDF

3. Kawasaki disease in adults: Observations in France and literature review

Author

Fraison, Jean-Baptiste, Sève, Pascal, Dauphin, Claire, Mahr, Alfred, Gomard-Mennesson, Emeline, Varron, Loig, Pugnet, Gregory, Landron, Cédric, Roblot, Pascal, Oziol, Eric, Chalhoub, Gihane, Galempoix, Jean-Marc, Humbert, Sébastien, Humbert, Philippe, Sbidian, Emilie, Grange, Florent, Bayrou, Olivier, Cathebras, Pascal, Morlat, Philippe, Epaulard, Olivier, Pavese, Patricia, Le Thi Huong, Du, Zoulim, Abdelkader, Stankovic, Katia, Bachelez, Hervé, Smail, Amar, Bachmeyer, C., Granel, Brigitte, Serratrice, Jacques, Brinchault, Graziella, Mekinian, Arsène, Costedoat-Chalumeau, Nathalie, Bourgarit-Durand, Anne, Puéchal, Xavier, Guillevin, Loïc, Piram, Maryam, Koné-Paut, Isabelle, and Fain, Olivier

Published
2016
Full Text
View/download PDF

4. Characteristics, outcome and treatments with cranial pachymeningitis: A multicenter French retrospective study of 60 patients

Author

Mekinian, Arsene, Maisonobe, Lucas, Boukari, Latifatou, Melenotte, Cléa, Terrier, Benjamin, Ayrignac, Xavier, Schleinitz, Nicolas, Sène, Damien, Hamidou, Mohamed, Konaté, Amadou, Guilpain, Philippe, Abisror, Noémie, Ghrenassia, Etienne, Lachenal, Florence, Cevallos, Ramiro, Roos-Weil, Richard, Du, Le Thi Huong, Lhote, Francois, Larroche, Claire, Bergmann, Jean-Francois, Humbert, Sébastien, Fraison, Jean Baptiste, Piette, Jean Charles, Guillevin, Loïc, Dhote, Robin, Amoura, Zahir, Haroche, Julien, and Fain, Olivier

Published
2018
Full Text
View/download PDF

5. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome

Author

Jasiek, Magali, Karras, Alexandre, Le Guern, Véronique, Krastinova, Evguenia, Mesbah, Rafik, Faguer, Stanislas, Jourde-Chiche, Noémie, Fauchais, Anne-Laure, Chiche, Laurent, Dernis, Emmanuelle, Moulis, Guillaume, Fraison, Jean-Baptiste, Lazaro, Estibaliz, Jullien, Perrine, Hachulla, Eric, Le Quellec, Alain, Rémy, Philippe, Hummel, Aurélie, Costedoat-Chalumeau, Nathalie, Ronco, Pierre, Vanhille, Philippe, Meas-Yedid, Vannary, Cordonnier, Carole, Ferlicot, Sophie, Daniel, Laurent, Seror, Raphaele, Mariette, Xavier, Thervet, Eric, François, Hélène, and Terrier, Benjamin

Published
2017
Full Text
View/download PDF

7. Cardiovascular outcome in adult-onset Kawasaki disease

Author

Peter, Elise, Fraison, Jean-Baptiste, Harbaoui, Brahim, Koné-Paut, Isabelle, Dauphin, Claire, Gomard-Mennesson, Emeline, Hervier, Baptiste, De Boysson, Hubert, Varron, Loig, Keraen, Jérémy, Pugnet, Grégory, Gobert, Delphine, Bachmeyer, Claude, Humbert, Sébastien, Landron, Cédric, Roblot, Pascal, Cathébras, Pascal, Gerfaud-Valentin, Mathieu, Weber, Emmanuelle, Jamilloux, Yvan, Fain, Olivier, and Seve, Pascal

Published
2021
Full Text
View/download PDF

9. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia

Author

Fraison, Jean-Baptiste, Mekinian, Arsène, Grignano, Eric, Kahn, Jean-Emmanuel, Arlet, Jean-Benoit, Decaux, Olivier, Denis, Guillaume, Buchdahl, Anne-Laure, Omouri, Mohamed, Maigne, Gwenola, Aouba, Achille, Leon, Nathalie, Berthier, Sabine, Liozon, Eric, Park, Sophie, Gardin, Claude, Lortholary, Olivier, Rossignol, Julien, Fenaux, Pierre, Fain, Olivier, and Braun, Thorsten

Published
2016
Full Text
View/download PDF

10. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: Multicenter study from the french uveitis network

Author

Vallet , Hélène, Seve , Pascal, Biard , Lucie, Fraison , Jean-Baptiste, Bielefeld , Philip, Perard , Laurent, Bienvenu , Boris, Abad , Sébastien, Rigolet , Aude, Deroux , Alban, Sène , Damien, Perlat , Antoinette, Marie , Isabelle, Feurer , Elodie, Hachulla , Eric, Fain , Olivier, Clavel , Gaëlle, Riviere , Sophie, Bouche , Pierre-Alban, Gueudry , Julie, Pugnet , Gregory, Le Hoang , Phuc, Resche Rigon , Matthieu, Cacoub , Patrice, Bodaghi , Bahram, Saadoun , David, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), E14, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Department of Internal Medicine, Hospices Civils de Lyon, Université de Lyon, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Jean Verdier [AP-HP], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Edouard Herriot [CHU - HCL], Service de médecine interne [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Avicenne [AP-HP], Centre de recherche en myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] (DHU - I2B), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC), Hôpital Michallon, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Saint-Antoine [AP-HP], ROTHSCHILD FOUNDATION, CHU de Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, PRES Université de Toulouse, Service de Néphrologie et Immunopathologie Clinique, Centre Hospitalier Universitaire de Toulouse, Immunologie - Immunopathologie - Immunothérapie (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Immunologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Ophtalmologie [CHU Pitié-Salpêtrière], The authors would like to thank Emmanuel Heron, Nathalie Tieulie, Gilles Blaison, Yoland Schoindre, Guillaume Moulis, Thomas Papo, Olivier Lidove, and Jean Sibilia for their collaboration and for follow-up of patients., Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Médecine interne et immunopathologie clinique [CHU Toulouse], Pôle IUCT [CHU Toulouse], CHU Pitié-Salpêtrière [APHP], Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Department of Internal Medicine, Hospices Civils de Lyon, Hôpital Saint Louis (Hôpital Saint Louis), Assistance Publique - Hôpitaux de Paris, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Hôpital Jean Verdier AP-HP Bondy, Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Hôpital avicenne, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [APHP], Université Grenoble Alpes (UGA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Service de médecine interne, Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, CHU Saint-Antoine [APHP], Service d'immunologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service d'ophtalmologie [CHU Pitié-Salpêtrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [AP-HP], Jonchère, Laurent, Hospices Civils de Lyon ( HCL ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Department of Internal Medicine, Hospices Civils de Lyon, Hôpital Saint Louis ( Hôpital Saint Louis ), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ), Hôpital Jean Verdier, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Division of Internal Medicine, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne-Université Paris 13 ( UP13 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Association française contre les myopathies ( AFM-Téléthon ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] ( DHU - I2B ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -CHU Pitié-Salpêtrière [APHP], Hôpital Michallon, CHU Grenoble, Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 ( UPD7 ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Rouen, Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases ( LYOS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Immunologie - Immunopathologie - Immunothérapie ( I3 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), and Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP]

Subjects
Adult, Male, safety, [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, anti-TNFα, Tumor Necrosis Factor-alpha, [ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Behcet Syndrome, Remission Induction, efficacy, Adalimumab, Anti-Inflammatory Agents, [ SDV.IMM.IMM ] Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, refractory inflammatory uveitis, Infliximab, Uveitis, Young Adult, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, [SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory Organs, Humans, Female, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs
Abstract

To analyze the factors associated with response to anti-tumor necrosis factor (anti-TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in patients with refractory noninfectious uveitis.This was a multicenter observational study of 160 patients (39% men and 61% women; median age 31 years [interquartile range 21-42]) with uveitis that had been refractory to other therapies, who were treated with anti-TNF (IFX 5 mg/kg at weeks 0, 2, 6, and then every 5-6 weeks [n = 98] or ADA 40 mg every 2 weeks [n = 62]). Factors associated with complete response were assessed by multivariate analysis. Efficacy and safety of IFX versus ADA were compared using a propensity score approach with baseline characteristics taken into account. Subdistribution hazard ratios (SHRs) and 95% confidence intervals (95% CIs) were calculated.The main etiologies of uveitis included Behçet's disease (BD) (36%), juvenile idiopathic arthritis (22%), spondyloarthropathy (10%), and sarcoidosis (6%). The overall response rate at 6 and 12 months was 87% (26% with complete response) and 93% (28% with complete response), respectively. The median time to complete response was 2 months. In multivariate analysis, BD and occurrence of5 uveitis flares before anti-TNF initiation were associated with complete response to anti-TNF (SHR 2.52 [95% CI 1.35-4.71], P = 0.004 and SHR 1.97 [95% CI 1.02-3.84], P = 0.045, respectively). Side effects were reported in 28% of patients, including serious adverse events in 13%. IFX and ADA did not differ significantly in terms of occurrence of complete response (SHR 0.65 [95% CI 0.25-1.71], P = 0.39), serious side effects (SHR 0.22 [95% CI 0.04-1.25], P = 0.089), or event-free survival (SHR 0.55 [95% CI 0.28-1.08], P = 0.083).Anti-TNF treatment is highly effective in refractory inflammatory uveitis. BD is associated with increased odds of response. IFX and ADA appear to be equivalent in terms of efficacy.

Published
2016
Full Text
View/download PDF

11. Dietary and Nondietary Triggers of Oral Ulcer Recurrences in Behçet's Disease

Author

Volle, Geoffroy, primary, Fraison, Jean-Baptiste, additional, Gobert, Delphine, additional, Goulenok, Tiphaine, additional, Dhote, Robin, additional, Fain, Olivier, additional, Gonzalez-Chiappe, Solange, additional, Lhote, François, additional, Papo, Thomas, additional, Thuillier, Aurélie, additional, Rivière, Sophie, additional, and Mahr, Alfred, additional

Published
2017
Full Text
View/download PDF

12. Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review.

Author

Wesner, Nadege, Drevon, Louis, Guedon, Alexis, Fraison, Jean Baptiste, Terrier, Benjamin, Trad, Salim, Kahn, Jean Emmanuel, Aouba, Achille, Gillard, Jerome, Ponsoye, Matthieu, Hanslik, Thomas, Gourguechon, Clement, Liozon, Eric, Laribi, Kamel, Rossignol, Julien, Hermine, Olivier, Seksik, Philippe, Adès, Lionel, Carrat, Fabrice, and Fenaux, Pierre

Subjects
CROHN'S disease, BEHCET'S disease, GASTROINTESTINAL diseases, JOINT pain, LITERATURE reviews, CANCER
Abstract

We report the 11 cases of +8-MDS/MPN associated with Behcet's-like syndrome and compare them with Behcet's disease and Crohn's disease, pool with literature cases for analysis. Data for patients with +8-MDS/MPN and Behçet's-like syndrome were collected from MINHEMON. Eleven patients had Behcet's-like syndrome and +8-MDS/MPN (median age 75 years [IQR 65–87]; M/F ratio 0.8). MDS and Behcet's-like syndrome were diagnosed at the same time (7/11, 64%). By comparison with 63 patients with idiopathic Behcet's disease without associated MDS, those with Behcet's-like syndrome and +8-MDS/MPN were older (median 75 vs 48 years; p =.0003) and had less pseudofolliculitis (11% vs 62%; p =.0045) and ocular impairment (0% vs 52%; p =.0008), but more frequent gastrointestinal involvement (60% vs 13%; p =.0005). By comparison with Crohn's disease, 39 patients with Behcet's-like syndrome and +8-MDS/MPN were significantly older (median 72 [53–78] vs 36 [27–45] years; p =.0002) and more frequently had oral aphtosis (97% vs 5%, p <.0001), skin features (50% vs 10%, p =.0005) and arthralgia (63% vs 20%, p =.03). Median survival did not differ between patients with Behcet's-like syndrome and +8-MDS/MPN and those with +8-MDS/MPN (n = 103) (47 vs 34 months, p =.61). AML-free survival did not differ between patients with MDS/MPN with and without Behcet's-like syndrome (p =.29). MDS/MPN with trisomy 8 can be associated with particular phenotype of ulcerative digestive disease resembling Behcet's or Crohn's disease and should be considered a single disease. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

14. Kawasaki disease in adults: observations in France and literature review Short title: Kawasaki disease in adults in France

Author

Fraison, Jean-Baptiste, Seve, Pascal, Dauphin, Claire, Mahr, Alfred, Gomard-Mennesson, Emeline, Varron, Loig, Pugnet, Gregory, Landron, Cédric, Roblot, Pascal, Oziol, Eric, Chalhoub, Gihane, Galempoix, Jean-Marc, Humbert, Sébastien, Humbert, Philippe, Sbidian, Emilie, Grange, Florent, Bayrou, Olivier, Cathebras, Pascal, Morlat, Philippe, Epaulard, Olivier, Pavese, Patricia, Du Boutin, Thi Huong, Zoulim, Abdelkader, Stankovic, Katia, Bachelez, Herve, Smail, Amar, Bachmeyer, C., Granel, Brigitte, Serratrice, Jacques, Brinchault, Graziella, Mekinian, Arsène, Costedoat-Chalumeau, Nathalie, Bourgarit-Durand, Anne, Puéchal, Xavier, Guillevin, Loïc, Piram, Maryam, Kone-Paut, Isabelle, Fain, Olivier, Jonchère, Laurent, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Médecine interne, Centre Hospitalier de Beziers, Centre Hospitalier de Montélimar, CH Montélimar, Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Médecine interne et immunopathologie clinique [CHU Toulouse], Pôle IUCT [CHU Toulouse], Service de Médecine Interne, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier de Charleville-Mezières, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CIC - CHU Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Saint-Etienne-Hôpital Nord - Saint-Etienne, Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Department of infectious diseases, CHU Grenoble, Service des Maladies Infectieuses, CHU Pitié-Salpêtrière [AP-HP], Service de médecine interne [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Tenon [AP-HP], Service de Néphrologie - Médecine Interne, CHU Amiens-Picardie-hôpital Sud, Centre Hospitalier Creil, Hôpital Nord [CHU - APHM], Service de pneumologie [Rennes] = Pneumology [Rennes], CHU Pontchaillou [Rennes], Centre de référence des maladies autoimmunes et systémiques rares, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pédiatrie Générale et Rhumatologie Pédiatrique, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service Pédiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, PRES Université de Toulouse, Service de Néphrologie et Immunopathologie Clinique, Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ), E14, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Department of Internal Medicine, Hospices Civils de Lyon, Université de Lyon, Service de médecine interne, hôpital Gabriel-Montpied, CHU Clermont-Ferrand, Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Centre hospitalier régional Metz-Thionville ( CHR Metz-Thionville ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Centre Hospitalier Universitaire de Reims ( CHU Reims ), CHU Saint-Antoine [APHP], CHU Pitié-Salpêtrière [APHP], Service de médecine interne [Caen], Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Caen, CHU Tenon [APHP], CHU Amiens-Picardie-Hôpital Sud, Service de pneumologie, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CHU Pontchaillou [Rennes], Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Department of Internal Medicine, Hospices Civils de Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC)

Subjects
Adult, [SDV] Life Sciences [q-bio], [ SDV ] Life Sciences [q-bio], intravenous immunoglobulin, [SDV]Life Sciences [q-bio], Mucocutaneous Lymph Node Syndrome
Abstract

International audience; Objective Kawasaki disease (KD) is a vasculitis that mostly occurs in young children and rarely in adults. We analyzed the characteristics of adult-onset KD (AKD) in France. Methods We collected retrospective and prospective data for patients with a diagnosis of KD occurring after the age of 18 years. Cases were obtained via various French medical networks and identified from the international literature. Results We included 43 patients of AKD at 26 institution from 1992 to 2015, with mean (SD) age 30 (11) years (range 18–68) and sex ratio (M/F) 1.2; 34 patients met the American Heart Association criteria and 9 were incomplete AKD. The median time to diagnosis was 13 days (interquartile range 8–21). The main symptoms were fever (100%), exanthema (98%), changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical adenitis (55%) and cardiac abnormalities (45%). Overall, 35% of patients showed large-vessel vasculitis: coronary vasculitis (26%) and coronary aneurysm (19%). Treatment was mostly intravenous immunoglobulins (79%) and aspirin (81%). Four patients showed myocardial infarction due to coronary vasculitis, but none were treated with IVIg because of late diagnosis. After a median follow-up of 5 months (range 1–117), persistent aneurysm was noted in 9% of cases. Damage was significantly lower with early treatment than late or no treatment (p = 0.01). Conclusion Given the high frequency of cardiac involvement and complications in this series of AKD, diagnosis and treatment should not be delayed, and early IVIg treatment seems to improve the outcome

Published
2015
Full Text
View/download PDF

15. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome

Author

Jasiek, Magali, primary, Karras, Alexandre, additional, Le Guern, Véronique, additional, Krastinova, Evguenia, additional, Mesbah, Rafik, additional, Faguer, Stanislas, additional, Jourde-Chiche, Noémie, additional, Fauchais, Anne-Laure, additional, Chiche, Laurent, additional, Dernis, Emmanuelle, additional, Moulis, Guillaume, additional, Fraison, Jean-Baptiste, additional, Lazaro, Estibaliz, additional, Jullien, Perrine, additional, Hachulla, Eric, additional, Le Quellec, Alain, additional, Rémy, Philippe, additional, Hummel, Aurélie, additional, Costedoat-Chalumeau, Nathalie, additional, Ronco, Pierre, additional, Vanhille, Philippe, additional, Meas-Yedid, Vannary, additional, Cordonnier, Carole, additional, Ferlicot, Sophie, additional, Daniel, Laurent, additional, Seror, Raphaele, additional, Mariette, Xavier, additional, Thervet, Eric, additional, François, Hélène, additional, and Terrier, Benjamin, additional

Published
2016
Full Text
View/download PDF

17. Inflammatory disorders associated with trisomy 8‐myelodysplastic syndromes: French retrospective case‐control study.

Author

Wesner, Nadege, Drevon, Louis, Guedon, Alexis, Fraison, Jean Baptiste, Trad, Salim, Kahn, Jean Emmanuel, Aouba, Achille, Gillard, Jerome, Ponsoye, Matthieu, Hanslik, Thomas, Gourguechon, Clement, Liozon, Eric, Laribi, Kamel, Rossignol, Julien, Hermine, Olivier, Adès, Lionel, Carrat, Fabrice, Fenaux, Pierre, Mekinian, Arsene, and Fain, Olivier

Subjects
MYELODYSPLASTIC syndromes, MYELOPROLIFERATIVE neoplasms, GENETICS of autoimmune diseases, IMMUNOLOGY of inflammation, COMMUNICABLE disease immunology
Abstract

Objective: We report cases of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) with trisomy 8 associated with inflammatory and autoimmune diseases (IADs). Method: Data for 21 patients with trisomy 8‐MDS/MPN and IADs were analyzed and compared to 103 patients with trisomy 8‐MDS/MPN without IADs. Results: The median age of MDS/MPN patients with IADs was 67 [59‐80]. The IADs were Behçet's‐like disease in 11 (52%) patients, inflammatory arthritis in 4 (19%) and Sjögren's syndrome, autoimmune hemolytic anemia, aseptic abscess, periarteritis nodosa, Sweet's syndrome and unclassified vasculitis in one patient each. Overall, 17/21 (81%) patients with IADs received treatment (88% with steroids), with complete and partial response in 7/17 (35%) and 8/17 (47%), respectively. The effect of MDS treatment on IADs could be assessed in seven patients receiving azacytidine: five achieved remission and two partial response. As compared with the 103 trisomy 8‐MDS/MPN cases without IADs, those with IADs were more often non‐European (P = 0.005) and had poor karyotype (P < 0.001). We found no difference in overall survival or acute myeloid leukemia progression between trisomy 8‐associated MDS/MPN with and without IADs. Conclusion: The spectrum of IADs associated with trisomy 8‐positive MDS/MPN is dominated by Behçet's‐like disease. Steroid therapy is effective, but mostly sparing therapies are necessary. Azacytidine could be an effective alternative. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Author

Fraison, Jean-Baptiste, primary, Mekinian, Arsène, additional, Grignano, Eric, additional, Kahn, Jean-Emmanuel, additional, Arlet, Jean-Benoît, additional, Decaux, Olivier, additional, Guillaume, Denis, additional, Buchdahl, Anne-Laure, additional, Omouri, Mohamed, additional, Maigne, Gwenola, additional, Aouba, Achille, additional, Leon, Nathalie, additional, Berthier, Sabine, additional, Liozon, Eric, additional, Park, Sophie, additional, Gardin, Claude, additional, Lortholary, Olivier, additional, Rossignol, Julien, additional, Fenaux, Pierre, additional, Fain, Olivier, additional, and Braun, Thorsten, additional

Published
2015
Full Text
View/download PDF

19. Abstract O.09: French observatory of Kawasaki disease in adults: 24 observations.

Author

Fraison, Jean-Baptiste, primary, Seve, Pascal, additional, Gommard-Menesson, Emmeline, additional, Dauphin, Claire, additional, Mahr, Alfred, additional, Landron, Cedric, additional, Nathalie, Costedoat-Chalumeau, additional, Epaulard, Olivier, additional, Boutin, Le Thi Huong, additional, Piram, Maryam, additional, Mékinian, Arsène, additional, Roblot, Pascal, additional, Oziol, Eric, additional, Hot, Arnaud, additional, Chalhoub, Gihane, additional, Galempoix, Jean-Marc, additional, Marchand, Guillaume, additional, Humbert, Sébastien, additional, Humbert, Philippe, additional, Morlat, Philippe, additional, Puéchal, Xavier, additional, Guillevin, Loic, additional, Koné-Paut, Isabelle, additional, and Fain, Olivier, additional

Published
2015
Full Text
View/download PDF

21. Efficacy and Safety of ANTI-TNF ALPHA in BEHCET Disease: A International Multicenter Registry of 122 Patients

Author

Vallet, Helene, Riviere, Sophie, Alban DEROUX, Moulis, Guillaume, Addimanda, Olga, Salvarani, Carlo, Lambert, Marc, Bielfeld, Philip, Seve, Pascal, Sibilia, Jean, Fraison, Jean Baptiste, Schoindre, Yoland, Marie, Isabelle, Perard, Laurent, Papo, Thomas, Sene, Damien, Leroux, Gaelle, Royant, Valerie, Perlat, Antoinette, Mariette, Xavier, Lidove, Olivier, Fain, Olivier, Moreuil, Claire, Blaison, Gilles, Le, Phuc Hoang, Hachulla, Eric, Wechsler, Bertrand, Bodaghi, Barham, Cacoub, Patrice, and Saadoun, David

22. Infliximab Versus Adalimumab in Severe Uveitis: Multicenter Study from the French Uveitis Network

Author

Vallet, Helene, Seve, Pascal, Biard, Lucie, Feurer, Elodie, Riviere, Sophie, Bielfeld, Philip, Perard, Laurent, Bienvenu, Boris, Abad, Sebastien, Rigolet, Aude, Deroux, Alban, Perlat, Antoinette, Damien SENE, Marie, Isabelle, Heron, Emmanuel, Hachulla, Eric, Fain, Olivier, Clavel, Gaelle, Sibilia, Jean, Tieulie, Nathalie, Schoindre, Yoland, Fraison, Jean Baptiste, Moulis, Guillaume, Papo, Thomas, Blaison, Gilles, Gueudry, Julie, Lidove, Olivier, Phuc Le Hoang, Chapelon, Catherine, Regon, Mathieu Resche, Cacoub, Patrice, Bodaghi, Bahram, and Saadoun, David

Catalog

Books, media, physical & digital resources
See catalog results